# 5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC

> **NCT05317000** · PHASE2 · RECRUITING · sponsor: **Barbara Burtness** · enrollment: 50 (estimated)

## Conditions studied

- Squamous Cell Carcinoma of Head and Neck

## Interventions

- **DRUG:** Combination 5-azacytidine and nivolumab
- **DRUG:** 5-azacytidine
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT05317000
- **Lead sponsor:** Barbara Burtness
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-23
- **Primary completion:** 2028-06-30
- **Final completion:** 2028-11-30
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-01-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05317000

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05317000, "5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05317000. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*